nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—REN—autonomic nervous system—conduct disorder	0.469	0.483	CbGeAlD
Captopril—ACE—autonomic nervous system—conduct disorder	0.2	0.206	CbGeAlD
Captopril—LTA4H—brain—conduct disorder	0.0588	0.0605	CbGeAlD
Captopril—REN—brain—conduct disorder	0.0454	0.0467	CbGeAlD
Captopril—MMP2—brain—conduct disorder	0.0417	0.0429	CbGeAlD
Captopril—MMP9—brain—conduct disorder	0.0363	0.0374	CbGeAlD
Captopril—SLC22A6—brain—conduct disorder	0.0324	0.0334	CbGeAlD
Captopril—F2—brain—conduct disorder	0.0317	0.0326	CbGeAlD
Captopril—ALB—brain—conduct disorder	0.0202	0.0208	CbGeAlD
Captopril—ACE—brain—conduct disorder	0.0193	0.0199	CbGeAlD
Captopril—CYP2D6—brain—conduct disorder	0.00947	0.00974	CbGeAlD
Captopril—ABCB1—brain—conduct disorder	0.00681	0.00701	CbGeAlD
Captopril—REN—Peptide hormone metabolism—CGA—conduct disorder	0.00605	0.214	CbGpPWpGaD
Captopril—ACE—Peptide hormone metabolism—CGA—conduct disorder	0.0027	0.0954	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0016	0.0563	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—CGA—conduct disorder	0.00114	0.0403	CbGpPWpGaD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—conduct disorder	0.00113	0.04	CbGpPWpGaD
Captopril—MMP2—FOXM1 transcription factor network—EP300—conduct disorder	0.00102	0.0361	CbGpPWpGaD
Captopril—MMP2—ATF-2 transcription factor network—EP300—conduct disorder	0.00078	0.0275	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000779	0.0275	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—conduct disorder	0.000743	0.0262	CbGpPWpGaD
Captopril—LTA4H—Metabolism—CGA—conduct disorder	0.000711	0.0251	CbGpPWpGaD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—conduct disorder	0.000611	0.0216	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—CGA—conduct disorder	0.000568	0.02	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000537	0.0189	CbGpPWpGaD
Captopril—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000529	0.0187	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—CGA—conduct disorder	0.00051	0.018	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—EP300—conduct disorder	0.000446	0.0157	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CGA—conduct disorder	0.000409	0.0144	CbGpPWpGaD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—EP300—conduct disorder	0.000405	0.0143	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—conduct disorder	0.000401	0.0141	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—EP300—conduct disorder	0.00039	0.0138	CbGpPWpGaD
Captopril—LTA4H—Metabolism—COMT—conduct disorder	0.000321	0.0113	CbGpPWpGaD
Captopril—LTA4H—Metabolism—MAOA—conduct disorder	0.000319	0.0112	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000309	0.0109	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000305	0.0108	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000301	0.0106	CbGpPWpGaD
Captopril—F2—G alpha (q) signalling events—HTR2A—conduct disorder	0.000296	0.0104	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CGA—conduct disorder	0.000288	0.0101	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000265	0.00935	CbGpPWpGaD
Captopril—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00024	0.00845	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CGA—conduct disorder	0.000231	0.00815	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—DRD4—conduct disorder	0.000229	0.00808	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000226	0.00799	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CGA—conduct disorder	0.00021	0.0074	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000196	0.00692	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CGA—conduct disorder	0.00016	0.00566	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—HTR2A—conduct disorder	0.000149	0.00527	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—EP300—conduct disorder	0.000142	0.00502	CbGpPWpGaD
Captopril—LTA4H—Metabolism—EP300—conduct disorder	0.000138	0.00486	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000132	0.00466	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—DRD4—conduct disorder	0.000129	0.00456	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—WASF1—conduct disorder	0.000129	0.00454	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000128	0.00452	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000127	0.00449	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000126	0.00446	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000125	0.00443	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CGA—conduct disorder	0.000124	0.00437	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000118	0.00415	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—DRD4—conduct disorder	0.000117	0.00414	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000103	0.00364	CbGpPWpGaD
Captopril—F2—Signaling Pathways—WASF1—conduct disorder	9.93e-05	0.0035	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EP300—conduct disorder	9.34e-05	0.0033	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—DRD4—conduct disorder	8.99e-05	0.00317	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—HTR2A—conduct disorder	8.44e-05	0.00298	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HTR2A—conduct disorder	7.66e-05	0.0027	CbGpPWpGaD
Captopril—F2—Hemostasis—EP300—conduct disorder	7.07e-05	0.0025	CbGpPWpGaD
Captopril—F2—Signaling Pathways—DRD4—conduct disorder	6.94e-05	0.00245	CbGpPWpGaD
Captopril—ALB—Metabolism—CGA—conduct disorder	5.88e-05	0.00207	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HTR2A—conduct disorder	5.86e-05	0.00207	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	5.36e-05	0.00189	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CGA—conduct disorder	5.15e-05	0.00182	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CGA—conduct disorder	4.85e-05	0.00171	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HTR2A—conduct disorder	4.53e-05	0.0016	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EP300—conduct disorder	3.11e-05	0.0011	CbGpPWpGaD
Captopril—ALB—Hemostasis—EP300—conduct disorder	2.81e-05	0.000991	CbGpPWpGaD
Captopril—ALB—Metabolism—COMT—conduct disorder	2.65e-05	0.000937	CbGpPWpGaD
Captopril—ALB—Metabolism—MAOA—conduct disorder	2.64e-05	0.00093	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—EP300—conduct disorder	2.56e-05	0.000902	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EP300—conduct disorder	2.4e-05	0.000846	CbGpPWpGaD
Captopril—ABCB1—Metabolism—COMT—conduct disorder	2.33e-05	0.000821	CbGpPWpGaD
Captopril—ABCB1—Metabolism—MAOA—conduct disorder	2.31e-05	0.000815	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—COMT—conduct disorder	2.19e-05	0.000773	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—MAOA—conduct disorder	2.18e-05	0.000768	CbGpPWpGaD
Captopril—ALB—Metabolism—EP300—conduct disorder	1.14e-05	0.000402	CbGpPWpGaD
Captopril—ABCB1—Metabolism—EP300—conduct disorder	9.97e-06	0.000352	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—EP300—conduct disorder	9.4e-06	0.000332	CbGpPWpGaD
